A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

Last updated:
2026-09-12
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFECT OF ELECOGLIPRON IN REDUCING RENAL OUTCOMES AND MORTALITY IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE (ELEVATE-CKD)

Intervention/treatment:
ELECOGLIPRON (AZD5004) / DAPAGLIFLOZIN
Medical condition:
CHRONIC KIDNEY DISEASE (CKD)
Protocol code:
D7265C00001
Control number:
501108
Status:
Recruiting
Approved:
May 12, 2026
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07753993
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
1-877-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Calgary, Alberta, T2R0X7
NOT_YET_RECRUITING
Research Site
Calgary, Alberta, T3R 1W9
NOT_YET_RECRUITING
Research Site
Edmonton, Alberta, T6G 2B7
NOT_YET_RECRUITING

British Columbia

Research Site
Vancouver, British Columbia, V5Y 3W2
NOT_YET_RECRUITING

Manitoba

Research Site
Winnipeg, Manitoba, R2V 3M3
NOT_YET_RECRUITING

New Brunswick

Research Site
Saint John, New Brunswick, E2L 4L2
NOT_YET_RECRUITING

Ontario

Research Site
London, Ontario, N6A 5A5
NOT_YET_RECRUITING
Research Site
London, Ontario, N6A 5W9
NOT_YET_RECRUITING
Research Site
Scarborough Village, Ontario, M1H 3G4
NOT_YET_RECRUITING
Research Site
Toronto, Ontario, M4G 3E8
RECRUITING
Research Site
Toronto, Ontario, M5B 1W8
NOT_YET_RECRUITING
Research Site
Toronto, Ontario, M5G 2N2
NOT_YET_RECRUITING
Research Site
Toronto, Ontario, M6G 1M2
NOT_YET_RECRUITING
Research Site
Waterloo, Ontario, N2T 0C1
RECRUITING

Quebec

Research Site
Montreal, Quebec, H1T 2M4
NOT_YET_RECRUITING
Research Site
Montreal, Quebec, H2X 0A9
NOT_YET_RECRUITING
Research Site
Montreal, Quebec, H3G 1A4
NOT_YET_RECRUITING
Research Site
Montreal, Quebec, H4J 1C5
NOT_YET_RECRUITING
Research Site
Sherbrooke, Quebec, J1H 5N4
NOT_YET_RECRUITING
Did you find what you were looking for?